138 related articles for article (PubMed ID: 11103934)
1. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.
Klein MA; Rüedi D; Nozaki M; Dell EW; Diserens AC; Seelentag W; Janzer RC; Aguzzi A; Hegi ME
Oncogene; 2000 Nov; 19(47):5329-37. PubMed ID: 11103934
[TBL] [Abstract][Full Text] [Related]
2. p53 transdominance but no gain of function in mouse brain tumor model.
Hegi ME; Klein MA; Rüedi D; Chène P; Hamou MF; Aguzzi A
Cancer Res; 2000 Jun; 60(11):3019-24. PubMed ID: 10850451
[TBL] [Abstract][Full Text] [Related]
3. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo.
Huang ZY; Baldwin RL; Hedrick NM; Gutmann DH
Oncogene; 2002 Feb; 21(9):1325-34. PubMed ID: 11857076
[TBL] [Abstract][Full Text] [Related]
4. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model.
Ding H; Shannon P; Lau N; Wu X; Roncari L; Baldwin RL; Takebayashi H; Nagy A; Gutmann DH; Guha A
Cancer Res; 2003 Mar; 63(5):1106-13. PubMed ID: 12615729
[TBL] [Abstract][Full Text] [Related]
5. A2B5 lineages of human astrocytic tumors and their recurrence.
Xia CL; Du ZW; Liu ZY; Huang Q; Chan WY
Int J Oncol; 2003 Aug; 23(2):353-61. PubMed ID: 12851684
[TBL] [Abstract][Full Text] [Related]
6. GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background.
Hede SM; Hansson I; Afink GB; Eriksson A; Nazarenko I; Andrae J; Genove G; Westermark B; Nistér M
Glia; 2009 Aug; 57(11):1143-53. PubMed ID: 19115382
[TBL] [Abstract][Full Text] [Related]
7. Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression.
Wilhelmsson U; Eliasson C; Bjerkvig R; Pekny M
Oncogene; 2003 May; 22(22):3407-11. PubMed ID: 12776191
[TBL] [Abstract][Full Text] [Related]
8. Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation.
Haapasalo H; Isola J; Sallinen P; Kalimo H; Helin H; Rantala I
Am J Pathol; 1993 May; 142(5):1347-51. PubMed ID: 7684193
[TBL] [Abstract][Full Text] [Related]
9. The p53 gene and its role in human brain tumors.
Bögler O; Huang HJ; Kleihues P; Cavenee WK
Glia; 1995 Nov; 15(3):308-27. PubMed ID: 8586466
[TBL] [Abstract][Full Text] [Related]
10. Transformation of type 1 astrocytes with N-ethyl-N-nitrosourea: establishment of an in vitro system and the role of the p53 gene.
Hiraga S; Arita N; Ohnishi T; Izumoto S; Taki T; Yamamoto H; Higuchi M; Hayakawa T
Glia; 1995 Jan; 13(1):51-63. PubMed ID: 7751056
[TBL] [Abstract][Full Text] [Related]
11. Ethnicity delineates different genetic pathways in malignant glioma.
Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
[TBL] [Abstract][Full Text] [Related]
12. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
13. Progression as exemplified by human astrocytic tumors.
Collins VP
Semin Cancer Biol; 1999 Aug; 9(4):267-76. PubMed ID: 10448114
[TBL] [Abstract][Full Text] [Related]
14. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas.
Ding H; Roncari L; Shannon P; Wu X; Lau N; Karaskova J; Gutmann DH; Squire JA; Nagy A; Guha A
Cancer Res; 2001 May; 61(9):3826-36. PubMed ID: 11325859
[TBL] [Abstract][Full Text] [Related]
15. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of mortalin expression in human brain tumors.
Takano S; Wadhwa R; Yoshii Y; Nose T; Kaul SC; Mitsui Y
Exp Cell Res; 1997 Nov; 237(1):38-45. PubMed ID: 9417864
[TBL] [Abstract][Full Text] [Related]
17. Malignant transformation of p53-deficient astrocytes is modulated by environmental cues in vitro.
Bögler O; Nagane M; Gillis J; Huang HJ; Cavenee WK
Cell Growth Differ; 1999 Feb; 10(2):73-86. PubMed ID: 10074901
[TBL] [Abstract][Full Text] [Related]
18. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
19. Comparative assessment of the functional p53 status in glioma cells.
Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
[TBL] [Abstract][Full Text] [Related]
20. Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes.
Junge CE; Lee CJ; Hubbard KB; Zhang Z; Olson JJ; Hepler JR; Brat DJ; Traynelis SF
Exp Neurol; 2004 Jul; 188(1):94-103. PubMed ID: 15191806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
